Lynparza in combination with abiraterone granted priority review in US
New therapy is aimed at patients with metastatic castration-resistant prostate cancer
Read More
Tag: abiraterone
ICR welcomes new advanced prostate cancer treatment guideline
NHS England has expanded access to targeted hormone therapies for advanced prostate cancer
Read More
NICE rejects Janssen’s Zytiga for early, aggressive prostate cancer
It is looking unlikely that Janssen’s Zytiga plus androgen deprivation therapy and prednisone/prednisolone will become routinely available on the NHS as a first-line treatment for patients with high-risk hormone-sensitive metastatic prostate cancer.
Read More
AZ, MSD’s Lynparza/abiraterone combo hits prostate cancer goals
AstraZeneca and MSD have presented data at ASCO showing improvement in radiologic progression-free survival in prostate cancer patients taking a combination of Lynparza and abiraterone.
Read More
Janssen’s Zytiga approved for earlier use in prostate cancer
European regulators are allowing earlier use of Janssen’s Zytiga in the treatment pathway for metastatic prostate cancer.
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
